

1	LAWRENCE R. KATZIN (CA SBN 142885)		
2	LKatzin@mofo.com NATALIE THINGELSTAD (CA SBN 255400)		
3	NThingelstad@mofo.com AMY C. DACHTLER (CA SBN 248589)		
4	ADachtler@mofo.com MORRISON & FOERSTER LLP		
5	425 Market Street San Francisco, California 94105-2482		
6	Telephone: (415) 268-6992 Facsimile: (415) 268-7522		
7	MARK L. LEVINE (admitted pro hac vice)		
8	mark.levine@bartlit-beck.com JASON L. PELTZ (admitted pro hac vice)		
9	jason.peltz@bartlit-beck.com BRIAN C. SWANSON (admitted pro hac vice)		
10	brian.swanson@bartlit-beck.com J. SCOTT MCBRIDE (admitted pro hac vice)		
11	scott.mcbride@bartlit-beck.com BARTLIT BECK HERMAN PALENCHAR & SCO	OTT LLP	
12	54 West Hubbard St., Suite 300 Chicago, IL 60654		
13	Telephone: (312) 494-4400 Facsimile: (312) 494-4440		
14	Attorneys for Defendants	IE AL THCADE	
15	BAYER CORPORATION, BAYER AG, BAYER HEALTHCARE LLC, AND BAYER SCHERING PHARMA AG		
16	UNITED STATES DISTRICT COURT		
17	NORTHERN DISTRICT OF CALIFORNIA		
18	SAN FRANCISCO DIVISION		
19			
20	ONYX PHARMACEUTICALS, INC.,	Case No. CV 09 2145 MHP	
21	Plaintiff,	DISCLOSURE STATEMENT	
22	v.		
23 24	BAYER CORPORATION, BAYER AG, BAYER HEALTHCARE LLC, AND BAYER SCHERING PHARMA AG		
25	Defendants.		
26	B 174 64 B 1 15 1 66 15		
27	Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, on behalf of Defendants Bayer AG		
28	and Bayer Schering Pharma AG, the undersigned certifies as follows:		
	DISCLOSURE STATEMENT	09 2145 CV 09 2145	1
	sf-2725703		

1	1. Bayer AG has no parent corporation, and no publicly held corporation owns 10% or		
2	more of Bayer AG's stock.		
3	2. Bayer Schering Pharma AG is a wholly-owned subsidiary of Bayer AG.		
4			
5	5		
6	Dated: August 12, 2009	LAWRENCE R. KATZIN NATALIE THINGELSTAD	
7	7	AMY C. DACHTLER MORRISON & FOERSTER LLP	
8	3	MARK L. LEVINE	
9)	JASON L. PELTZ BRIAN C. SWANSON	
10		J. SCOTT MCBRIDE BARTLIT BECK HERMAN PALENCHAR &	
11		SCOTT LLP	
12			
13		By: /s/ Lawrence R. Katzin LAWRENCE R. KATZIN	
14		Attorneys for Defendants BAYER CORPORATION, BAYER AG,	
15		BAYER HEALTHCARE LLC, AND BAYER SCHERING PHARMA AG	
1617			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			

DISCLOSURE STATEMENT sf-2725703

09 2145 CV 09 2145

2